Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

Beginning with opium, the “joy plant,” which has been used for 10,000 years, Thomas Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

When Elon Musk was a kid in South Africa, he was regularly beaten by bullies. One day a group pushed him down some concrete steps and kicked him until his face was a swollen ball of flesh. He was in the hospital for a week. But the physical scars were minor compared to the emotional ones inflicted by his father, an engineer, rogue, and charismatic fantasist.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

The bestselling author of Leonardo da Vinci and Steve Jobs returns with a “compelling” (The Washington Post) account of how Nobel Prize winner Jennifer Doudna and her colleagues launched a revolution that will allow us to cure diseases, fend off viruses, and have healthier babies.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made “the impossible possible”—creating, testing, and manufacturing a safe and effective COVID-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer overcame a series of crises that were compounded by social and political unrest.

Innovations rarely come from “experts.” Elon Musk was not an “electric car person” before he started Tesla. When it comes to improbable innovations, a legendary tech VC told Sebastian Mallaby, the future cannot be predicted, it can only be discovered. It is the nature of the venture-capital game that most attempts at discovery fail, but a very few succeed at such a scale that they more than make up for everything else. That extreme ratio of success and failure is the power law that drives the VC business, all of Silicon Valley, the wider tech sector, and, by extension, the world.

Ray Dalio does not want you to listen to this audiobook. Late last year, when the billionaire founder of Bridgewater Associates, the largest hedge fund on the planet, announced that he was stepping down from the company he started out of his apartment nearly 50 years ago, the news made headlines around the world. Dalio cultivated an aura of international admiration and fame thanks to his company’s eye-popping success, coupled with a mystique he encouraged with frequent media appearances, celebrity hobnobbing, and his bestselling book, Principles.

From the author of The Emperor of All Maladies, winner of the Pulitzer Prize, and The Gene, a #1 New York Times bestseller, comes his most spectacular book yet, an exploration of medicine and our radical new ability to manipulate cells. Rich with Mukherjee’s revelatory and exhilarating stories of scientists, doctors, and the patients whose lives may be saved by their work, The Song of the Cell is the third book in this extraordinary writer’s exploration of what it means to be human.

The Emperor of All Maladies reveals the many faces of an iconic, shape-shifting disease that is the defining plague of our generation. The story of cancer is a story of human ingenuity, resilience, and perseverance but also of hubris, arrogance, paternalism, and misperception, all leveraged against a disease that, just three decades ago, was thought to be easily vanquished in an all-out "war against cancer".

You wake up and feel a tickle in your throat. Your head hurts. You’re mildly annoyed as you get the kids ready for school and dress for work yourself. Meanwhile, an epic war is being fought, just below your skin. Millions are fighting and dying for you to be able to complain as you head out the door. So what, exactly, is your immune system? In Immune, Philipp Dettmer, the brains behind the most popular science channel on YouTube, takes listeners on a journey through the fortress of the human body and its defenses.

You may be surprised to learn that microchips are the new oil—the scarce resource on which the modern world depends. Today, military, economic, and geopolitical power are built on a foundation of computer chips. Virtually everything—from missiles to microwaves—runs on chips, including cars, smartphones, the stock market, even the electric grid. Until recently, America designed and built the fastest chips and maintained its lead as the #1 superpower, but America’s edge is in danger of slipping, undermined by players in Taiwan, Korea, and Europe taking over manufacturing.

In Regenesis, George Church and science writer Ed Regis explore the possibilities of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. These technologies - far from the out-of-control nightmare depicted in science fiction - have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span.

Lee Hood did that rarest of things. He enabled scientists to see things they couldn't see before and do things they hadn't dreamed of doing. Scientists can now sequence complete human genomes in a day, setting in motion a revolution that is personalizing medicine. Hood, a son of the American West, was an unlikely candidate to transform biology. But with ferocious drive, he led a team at Caltech that developed the automated DNA sequencer, the tool that paved the way for the Human Genome Project.

Finding the right venture capitalist to back your start-up is a challenge. Even if you manage to get backing, you want your VC to be a partner, not some dictator who will undermine your vision and take control of your life's work. Jeffrey Bussgang is one of a very few people who have played on both sides of this high-stakes game. Now he draws on his unique perspective to offer high-level insights, colorful stories, and practical advice. He reveals how to get noticed, perfect a pitch, and negotiate a partnership that works for everyone.

American taxpayers spend $30 billion annually funding biomedical research, but over half of these studies can't be replicated due to poor experimental design, improper methods, and sloppy statistics. Bad science doesn't just hold back medical progress, it can sign the equivalent of a death sentence for terminal patients. In Rigor Mortis, Richard Harris explores these urgent issues with vivid anecdotes, personal stories, and interviews with the top biomedical researchers. We need to fix our dysfunctional biomedical system - before it's too late.

Few were ready when a mysterious respiratory illness emerged in Wuhan, China, in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world’s biggest drug and vaccine makers were slow to react or couldn’t muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization.

A bold new remedy for the sprawling and wasteful health care industry. In this provocative book, Jonathan Bush, cofounder and CEO of athenahealth, calls for a revolution in health care to give customers more choices, freedom, power, and information, and at far lower prices.

Open provides valuable lessons in leadership in times of crisis, management decision-making under the pressure of extraordinary growth, and the power of a unique, pervasive culture. Open tells the incredible story of Compaq’s meteoric rise from humble beginnings to become the PC industry leader in just over a decade. Along the way, Compaq helped change the face of computing while establishing the foundation for today’s world of tablets and smart phones.

A behind-the-scenes, revelatory history of McKinsey & Company, America's most influential and controversial business consulting firm, told by one of the nation's leading financial journalists. In The Firm, Duff McDonald uncovers how these high-powered, high-priced business savants have ushered in waves of structural, financial, and technological shifts. With unrivaled access to company documents and current and former employees, McDonald reveals the inner workings of what just might be the most influential private organization in America.

This first real look inside Team Obama mixes political warfare and big-business shakeups in equal proportions, and comes from a uniquely informed source. Steve Rattner is not just the man brought in by the president to save the auto industry, he is a former New York Times financial reporter who also earned a place among the top tier of Wall Street's most informed investment bankers and corporate experts.

In 1990, IBM had its most profitable year ever. By 1993, the company was on a watch list for extinction, victimized by its own lumbering size, an insular corporate culture, and the PC era IBM had itself helped invent.

Moneyball meets medicine in this remarkable chronicle of one of the greatest scientific quests of our time - the groundbreaking program to answer the most essential question for humanity: How do we live and die? - and the visionary mastermind behind it.

In late February 2020, Dr. Deborah Birx—a lifelong federal health official who had worked at the CDC, the State Department, and the US Army across multiple presidential administrations—was asked to join the Trump White House Coronavirus Task Force and assist the already faltering federal response to the Covid-19 pandemic. For weeks, she’d been raising the alarm behind the scenes about what she saw happening in public—from the apparent lack of urgency at the White House to the routine downplaying of the risks to Americans.

No Better Time tells of a young, driven mathematical genius who wrote a set of algorithms that would create a faster, better Internet. It's the story of a beautiful friendship between a loud, irreverent student and his soft-spoken MIT professor, of a husband and father who spent years struggling to make ends meet only to become a billionaire almost overnight with the success of Akamai Technologies, the Internet content delivery network he cofounded with his mentor.

From the cranberry bogs of Massachusetts to the classrooms of Singapore and Finland, from tiny start-ups to global engineering firms and beloved American organizations like Ocean Spray, Eileen Fisher, Gore, and Boston Scientific, Heffernan discovers ways of living and working that foster creativity, spark innovation, reinforce our social fabric, and feel so much better than winning.

Built To Last, the defining management study of the 90s, showed how great companies triumph over time and how long-term sustained performance can be engineered into the DNA of an enterprise from the very beginning. But what about companies that are not born with great DNA? How can good companies, mediocre companies, even bad companies achieve enduring greatness?

When pioneering business journalist and Inc. magazine editor at large Bo Burlingham wrote Small Giants, it became an instant classic for its original take on a common business problem - how to handle the pressure to grow. Now Burlingham is back to tackle an even more common problem - how to exit your company well. Sooner or later, all entrepreneurs leave their businesses and all businesses get sold, given away, or liquidated.

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

The search to find medicines is as old as disease, which is to say as old as the human race. Through serendipity - by chewing, brewing, and snorting - some Neolithic souls discovered opium, alcohol, snakeroot, juniper, frankincense, and other helpful substances. Ötzi the Iceman, the 5,000-year-old hunter frozen in the Italian Alps, was found to have whipworms in his intestines and Bronze Age medicine, a worm-killing birch fungus, knotted to his leggings.